Signaling Pathways in the Pathogenesis of Barrett’s Esophagus and Esophageal Adenocarcinoma
Barrett’s esophagus, Barrett’s Oesophagus, carcinogenesis, dysplasia, Dysplasie, esophageal adenocarcinoma, Inflammatorische Signalwege, inflammatory signaling pathways, intestinal metaplasia, Intestinale Metaplasie, Karzinogenese, mutational load, Mutationslast, oesophageales Adenokarzinom, p53
Maslenkina K, et al. Signaling Pathways in the Pathogenesis of Barrett’s Esophagus and Esophageal Adenocarcinoma. Int J Mol Sci 2023 May 26;24(11):9304. doi:10.3390/ijms24119304
Noninferiority of Artificial Intelligence–Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics
digital pathology, digitale Pathologie, Mamma carcinoma
Abele N, Tiemann K, Krech T, Wellmann A, Schaaf C, Länger F, et al. Noninferiority of Artificial Intelligence–Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics. Mod Panthol 2023 Mar;36(3):100033. doi:10.1016/j.modpat.2022.100033
Mast Cells in Regeneration of the Skin in Burn Wound with Special Emphasis on Molecular Hydrogen Effect
Brandwunde, burn wound, fibröse extrazelluläre Matrix, fibrous extracellular matrix, Haut, Mast cells, Mastzellen, molecular hydrogen, molekularer Wasserstoff, Regeneration, Skin
Atiakshin D, et al. Mast Cells in Regeneration of the Skin in Burn Wound with Special Emphasis on Molecular Hydrogen Effect. Pharmaceuticals (Basel) 2023 Feb 24;16(3):348. doi:10.3390/ph16030348
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
disease monitoring, HER2 Mutation, Krankheitsmonitoring, Liquid Biopsy, Trastuzumab Deruxtecan
Falk M, et al. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Curr Oncol 2023 Jan 30;30(2):1692-1698. doi:10.3390/curroncol30020130
The Remodeling of Dermal Collagen Fibrous Structures in Mice under Zero Gravity: The Role of Mast Cells
collagen fibers, extracellular matrix,, extrazelluläre Matrix, Fibroblasten, fibroblasts, Haut, Kollagenfasern, Mast cells, Mastzellen, Schwerelosigkeit, Skin, zero gravity
Shishkina V, et al. The Remodeling of Dermal Collagen Fibrous Structures in Mice under Zero Gravity: The Role of Mast Cells. Int J Mol Sci 2023; Jan 18;24(3):1939. doi: 10.3390/ijms24031939
Genetic alterations affecting the C-terminus of cyclin D1 are recurrent events in mantle cell lymphoma
Laccarino I, et al. Genetic alterations affecting the C-terminus of cyclin D1 are recurrent events in mantle cell lymphoma. Histopathology 2023 Jan;82(2):371-373. doi:10.1111/his.14815. Epub 2022 Oct 13
Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab
Endometrial carcinoma, Endometriumkarzinom, Fluoreszenz in situ Hybridisierung (FISH)
Weimer J, Hüttmann M, Nusilati A, Andreas S, Röseler J, Tribian N, et al. Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab. J Cell Mol Med. 2023 Jan 10;27(3):379-391. doi:10.1111/jcmm.17658
A Formylglycine-Peptide for the Site-Directed Identification of Phosphotyrosine-Mimetic Fragments
Formylglycin, formylglycine, fragment ligation, fragment-based drug discovery, Fragment-basierte Arzeimittelforschung, Fragmentligation, phosphatase inhibitors, Phosphataseinhibitoren, site-directed screening
Tiemann M, et al. A Formylglycine-Peptide for the Site-Directed Identification of Phosphotyrosine-Mimetic Fragments. Chemistry 2022 Oct 12;28(57):e202201282. doi:10.1002/chem.202201282
Recent Advances in Castleman Disease
Castleman disease, HHV-8, Morbus Castleman, Multicentric CD, Multizentrisches CD, Siltuximab, Unicentric CD, Unizentrisches CD
Hoffmann C, et al. Recent Advances in Castleman Disease. Oncol Res Treat 2022;45(11):693-704. doi:10.1159/000526640. Epub 2022 Oct 11
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
G2032R, Liquid Biopsy, Lorlatinib, NSCLC, resistance mutation, Resistenzmutation, ROS1
Jóri, B.; Falk, M.; Hövel, I.; Weist, P.; Tiemann, M.; Heukamp, L.C.; Griesinger, F. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Curr. Oncol. 2022, 29, 6628–6634. https://doi.org/10.3390/ curroncol29090520